Tectonic Therapeutics TECX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $71.32M+63.7% | $63.49M+53.5% | $56.3M+42.9% | $53.69M+61.6% | $43.58M+24.8% | ||
| $21.72M+9.9% | $20.55M+23.4% | $20.21M+44.3% | $20.56M+92.9% | $19.76M+142% | ||
| $93.04M+46.9% | $84.04M+44.8% | $76.51M+43.3% | $74.26M+69.2% | $63.35M+47.0% | ||
| $93.04M+46.9% | $84.04M+44.8% | $76.51M+43.3% | $74.26M+69.2% | $63.35M+47.0% | ||
| -$93.04M-46.9% | -$84.04M-44.8% | -$76.51M-43.3% | -$74.26M-69.2% | -$63.35M-47.0% | ||
| $51K-46.3% | $63K-40.6% | $73K-38.1% | $84K-34.9% | $95K-32.6% | ||
| $11.03M+71.1% | $11.3M+165% | $10.47M+294% | $9.52M+1,084% | $6.45M+808% | ||
| $10.78M+130% | $11.12M+31,657% | $10.19M+13,163% | $9.25M+578% | $4.68M+1,014% | ||
| —— | -$72.92M-25.8% | -$66.32M— | -$65M— | -$58.67M— | ||
| $26.43M+66.1% | $17.14M+12.3% | $16.89M— | $16.89M— | $15.91M— | ||
| -$83.49M-42.3% | -$74.15M-27.9% | -$67.3M-25.8% | -$65.98M-44.0% | -$58.67M-34.6% | ||
| -$4.46— | -$4.05— | —— | —— | —— | ||
| -$4.46— | -$4.05— | —— | —— | —— | ||
| 74.5M+72.0% | 72.9M+165% | 63M+210% | 59.1M+757% | 43.3M+732% | ||
| 74.5M+72.0% | 72.9M+165% | 63M+210% | 59.1M+757% | 43.3M+732% | ||
| -$61K-239% | -$105K-10,600% | -$9K+89.4% | $1K+101% | $44K+172% | ||
| $83.55M+42.5% | $74.26M+28.1% | $67.31M+25.7% | $65.98M+43.8% | $58.62M+34.3% | ||
| -$200K-43.9% | -$119K+76.7% | -$206K-2,189% | -$182K-5,967% | -$139K-2,217% | ||
| -$93.04M-46.9% | -$84.04M-44.8% | -$76.51M-43.3% | -$74.26M-69.2% | -$63.35M-47.0% | ||
| -$91.72M-48.6% | -$82.66M-46.6% | -$74.96M-44.5% | -$72.63M-71.2% | -$61.72M-48.1% | ||
| -$91.72M-48.6% | -$82.66M-46.6% | -$74.96M-44.5% | -$72.63M-71.2% | -$61.72M-48.1% | ||
| -$93.04M-46.9% | -$84.04M-44.8% | -$76.51M-43.3% | -$74.26M-69.2% | -$63.35M-47.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Tectonic Therapeutics profitable?
- Tectonic Therapeutics is not currently profitable: it reported a net loss of $83.5M over the trailing twelve months.
- What is Tectonic Therapeutics's earnings per share?
- Tectonic Therapeutics's diluted EPS over the trailing twelve months is $-4.46.
- Where does Tectonic Therapeutics's income statement data come from?
- Every line is extracted from Tectonic Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.